The Novo-TTF 100A system is a novel antitumor treatment modality that demonstrated a survival effect for primary glioblastoma in a multicenter open-label randomized phase III trial. We used this treatment modality for 3 glioblastoma patients in Nihon University Itabashi Hospital. Here, we report the clinical courses of these 3 patients. Patient 1 was a 52-year-old male with left temporal glioblastoma who was treated via the Novo-TTF 100A system for 3 months. Patient 2 was a 62-year-old female with right thalamic glioblastoma who was treated via the Novo-TTF 100A system for 13 months. Patient 3 was a 38-year-old male with left frontal glioblastoma who was treated via the Novo-TTF 100A system for 6 months. Patient 1 died 12 months after surgery, and Patient 2 died 18 months after surgery. Patient 3 is being treated via the Novo-TTF 100A system. The details of the treatment course are described in this article.

Background Conjunctival chemosis (CC) is an extremely rare symptom of pituitary neuroendocrine tumor (PitNET). We report an extremely rare case of PitNET manifesting as severe CC. Case presentation A 48-year-old male was admitted to our hospital with severe CC, proptosis, and ptosis of the right eye. Magnetic resonance imaging demonstrated the tumor mass invading the cavernous sinus (CS) with cystic lesion. The patient underwent emergent endoscopic transsphenoidal surgery, and the pathological diagnosis was PitNET. CC of the right eye remarkably improved after the surgery. Glucocorticoid therapy was performed for right oculomotor nerve palsy, which rapidly improved. The postoperative course was uneventful and the patient was discharged from our hospital without hormone replacement. Conclusions CC caused by CS invasion of PitNET can be cured by early surgical treatment. Therefore, PitNET is important to consider in the differential diagnosis of CC.

Methotrexate (MTX)-associated lymphoproliferative disorder (MTX-LPD) is a known adverse event of MTX and rarely originates in the central nervous system (CNS). There are few case reports related to CNS LPDs; therefore, an effective treatment has not been established. We report a case of primary CNS MTX-LPD treated with a new combination chemotherapy consisting of rituximab, procarbazine, methotrexate, and vincristine (R-MPV therapy). A 56-year-old woman presented with chief complaints of headache, memory disturbance, and gait disturbance. She had taken MTX for rheumatoid arthritis for 25 years. Magnetic resonance imaging demonstrated tumor lesions in the left frontal and occipital lobes. The tumor was removed via craniotomy and diagnosed as MTX-LPD. MTX therapy was discontinued, but no tumor regression was observed. Although R-MPV therapy was started, no obvious regression was obtained. The patient died after 4 courses of R-MPV therapy. If chemotherapy achieves limited effects for patients with CNS MTX-LPD, early introduction of radiotherapy or change to other chemotherapy should be considered.